EUCTR2015-003514-24-IT进行中（未招募）1 期
Phase III study, double blind, placebo controlled, to evaluate the efficacy and the safety of an omega-3 based drug, in patients with primary tinnitus. - Efficacy of omega-3 on primary tinnitus
IBSA FARMACEUTICI ITALIA SR0 个研究点目标入组 100 人开始时间: 2021年5月24日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients of both gender with age 18-80 years.
- •Diagnosis of primary tinnitus (level 3-5, according to THI).
- •Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Controindications or hypersensitivity to Olevia or to one of its components.
- •Secondary tinnitus.
- •Haepatic impairment.
- •Moderate to severe renal impairment.
- •Ischemic heart disease
研究者
相似试验
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist TherapyEUCTR2010-022758-18-HUJanssen-Cilag International N.V.675
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVRespiratory Syncytial VirusMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002023-11-DEJanssen-Cilag International NV737
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately to Severely Active Crohn’s DiseaseModerately to severely active Crohn's diseaseMedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-022759-42-HUJanssen-Cilag International N.V.612
进行中（未招募）
1 期
Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate CancerEUCTR2017-003295-31-HUPfizer Inc., 235 East 42nd Street, New York, NY 100171,037
进行中（未招募）
1 期
A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- andHigh-risk Pulmonary arterial hypertension (PAH) Patients.EUCTR2021-000199-12-ITACCELERON PHARMA INC.662